HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2004
Business Overview: The Company designs, develops, manufactures, and distributes life science instrumentation and consumables for drug discovery and research. Revenue growth is driven by a strategy of new product development, strategic partnerships, and acquisitions. A significant portion of revenue (approx. 33% in Q2 2004) comes from capital equipment, which introduces seasonality and volatility.

Key Financial Metrics

Note: Working Capital calculated as Total Current Assets ($56,394) minus Total Current Liabilities ($14,284).

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 7% year-over-year for the six months ended June 30, 2004 ($44.6M vs. $41.8M), primarily driven by acquisitions (BioRobotics, Hoefer, KD Scientific) and favorable foreign exchange rates (strengthening of the British Pound and Euro).
• Profitability Decline: Net income for the six months dropped significantly to $247,000 from $1.521 million in the prior year period. Operating income fell to $771,000 from $3.341 million.
• Expense Increases:
  • G&A Expenses: Increased 24% ($7.1M vs. $5.7M) due to restructuring costs ($0.5M) and acquisition-related integration costs.
  • Amortization: Increased 49% ($2.0M vs. $1.4M) due to new intangible assets from acquisitions.
  • Interest Expense: Net interest expense rose to $272,000 (six months) from $26,000, reflecting increased debt usage to fund acquisitions.
• Acquisition Activity: The Company acquired KD Scientific, Inc. in March 2004 for approximately $6.8 million, funded by a drawdown on its credit facility.

Guidance, Outlook, and Risks

• Outlook: Management expects organic revenue growth in 2004 to be below historic levels. They anticipate lower revenues in genomics, proteomics, and high-throughput screening lines compared to 2003 due to market uncertainty and a lack of focus in the first half of the year.
• Restructuring: An action plan and restructuring were implemented at the Genomic Solutions subsidiary in Q2 2004 to improve operating metrics. These costs adversely impacted Q2 earnings and are expected to impact the second half of 2004.
• Liquidity and Capital: The Company has a $20 million credit facility with Brown Brothers Harriman, with approximately $18.1 million drawn as of June 30, 2004. Management believes current resources are sufficient for at least 12 months.
• SEC Filing Status: The Company is currently prohibited from accessing public equity markets due to an outstanding amendment to a Form 8-K regarding a previous acquisition. They are ineligible to use Form S-3 until this is resolved and 12 months have passed.
• Legal Proceedings: An arbitration appeal regarding the former owner of Harvard Apparatus (Paul D. Grindle) is pending with the Massachusetts Appeals Court. The Company previously prevailed in the lower court.
• Key Risks: Dependence on GE Healthcare for distribution (approx. 16-18% of revenue); integration risks of recent acquisitions; foreign currency fluctuations; and the cyclical nature of capital equipment sales.

Investor Verification Checklist

• Form 8-K Status: Verify the resolution of the outstanding Form 8-K amendment to confirm when the Company regains access to public equity markets.
• Genomic Solutions Performance: Monitor the effectiveness of the restructuring plan at Genomic Solutions and its impact on future profitability.
• Debt Covenants: Review compliance with financial covenants in the $20 million credit facility, particularly regarding income and debt coverage ratios.
• Acquisition Integration: Assess the realization of synergies from the KD Scientific, BioRobotics, and Hoefer acquisitions, specifically regarding revenue growth vs. increased amortization and G&A costs.
• Legal Appeal: Track the status of the Grindle arbitration appeal to ensure no material adverse judgment is rendered.